CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CKMT1A | Creatine kinase, mitochondrial 1A | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Mixed |
CKMT1B | Creatine kinase, mitochondrial 1B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CKMT2 | Creatine kinase, mitochondrial 2 (sarcomeric) | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CNR2 | Cannabinoid receptor 2 (macrophage) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPS1 | Carbamoyl-phosphate synthase 1, mitochondrial | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CRBN | Cereblon | Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CSF2RA | Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CSF2RB | Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CYSLTR1 | Cysteinyl leukotriene receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
CYSLTR2 | Cysteinyl leukotriene receptor 2 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
DCK | Deoxycytidine kinase | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
DDC | Dopa decarboxylase (aromatic L-amino acid decarboxylase) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
DHFR | Dihydrofolate reductase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Mixed |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DRD1 | Dopamine receptor D1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
DRD2 | Dopamine receptor D2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EDNRB | Endothelin receptor type B | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGF | Epidermal growth factor | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Group enriched |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ELANE | Elastase, neutrophil expressed | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ERBB4 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
ESR2 | Estrogen receptor 2 (ER beta) | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
ESRRG | Estrogen-related receptor gamma | FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
F5 | Coagulation factor V (proaccelerin, labile factor) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
F8 | Coagulation factor VIII, procoagulant component | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |